The estimated Net Worth of Diana Hausman is at least $1.26 Milion dollars as of 9 May 2024. Diana Hausman owns over 3,356 units of Zentalis Pharmaceuticals, Llc stock worth over $1,215,097 and over the last 6 years Diana sold ZNTL stock worth over $42,353.
Diana has made over 5 trades of the Zentalis Pharmaceuticals, Llc stock since 2020, according to the Form 4 filled with the SEC. Most recently Diana sold 3,356 units of ZNTL stock worth $42,353 on 9 May 2024.
The largest trade Diana's ever made was exercising 40,000 units of Zentalis Pharmaceuticals, Llc stock on 14 September 2020 worth over $545,600. On average, Diana trades about 5,450 units every 103 days since 2019. As of 9 May 2024 Diana still owns at least 373,876 units of Zentalis Pharmaceuticals, Llc stock.
You can see the complete history of Diana Hausman stock trades at the bottom of the page.
Diana's mailing address filed with the SEC is C/O ZENTALIS PHARMACEUTICALS, INC., 1359 BROADWAY, SUITE 801, NEW YORK, NY, 10018.
Over the last 4 years, insiders at Zentalis Pharmaceuticals, Llc have traded over $106,453,887 worth of Zentalis Pharmaceuticals, Llc stock and bought 5,536,611 units worth $121,990,782 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management Company,... a Anthony Y Sun. On average, Zentalis Pharmaceuticals, Llc executives and independent directors trade stock every 11 days with the average trade being worth of $188,516. The most recent stock trade was executed by Cam Gallagher on 31 May 2024, trading 9,597 units of ZNTL stock currently worth $114,972.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Zentalis Pharmaceuticals, Llc executives and other stock owners filed with the SEC include: